InsidersTradesSigma
Discover the detailed record of transactions filed by Ryali Sriram, Chief Financial Officer. Director active across 1 companies, notably Eiger BioPharmaceuticals, Inc.. Aggregated, 2 disclosures have been published. Total volume traded: €12k. The latest transaction was filed on 14 March 2022 (Cession). Regulator: SEC (Form 4). All data is openly available.
2 of 2 declarations
Sriram Ryali is the Chief Financial Officer at Eiger BioPharmaceuticals, Inc. He is responsible for the company's financial management, including budgeting and financial analysis. With a strong background in the industry, he plays a key role in strategic financial decision-making. His expertise is essential in ensuring the financial health of Eiger BioPharmaceuticals, Inc.